跳至主要内容
临床试验/NCT00154206
NCT00154206已完成4 期

A Multicenter, Open, Single Arm, Pilot Study to Evaluate Efficacy, Tolerability and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion and Steroids in Pediatric de Novo Renal Transplant Patients

Novartis Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2004年9月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
15
试验地点
1
主要终点
Incidence of biopsy-proven-acute-rejection and treatment failure (defined by graft loss and/or biopsy-proven-acute-rejection and/or death and/or lost to follow-up and/or study discontinuation) within the 6 and 12 months post transplantation

研究概览

简要总结

The aim of this pilot study is to evaluate efficacy and tolerability of EC-MPS b.i.d, with Cyclosporine microemulsion and steroids in pediatric de novo renal transplant patients. Safety and doses variations are also evaluated.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
5 Years 至 16 Years(Child)
性别
All
接受健康志愿者
否

入选标准

  • •Recipients of a primary renal transplantation
  • •Recipients of a renal transplantation only

排除标准

  • •Recipients of a multi-organ transplantation
  • •Unable to take an oral medication
  • •Requiring an induction therapy with polyclonal, monoclonal antibodies (OKT3, ATG, ALG).
  • •Other protocol-defined inclusion / exclusion criteria may apply

结局指标

主要结局

Incidence of biopsy-proven-acute-rejection and treatment failure (defined by graft loss and/or biopsy-proven-acute-rejection and/or death and/or lost to follow-up and/or study discontinuation) within the 6 and 12 months post transplantation

次要结局

  • Within the 6 and 12 months post transplantation
  • Incidence of acute rejection resistant to steroids
  • Incidence of graft loss and death
  • Renal function by creatinine and creatinine clearance (Schwartz formula)
  • Incidence of premature study drug discontinuation due to safety reason
  • Pharmacokinetic profile of Myfortic.
  • Frequency of adverse events, incidence of clinically notable laboratory abnormalities, and change on vital signs.

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验